DEPARLE NANCY ANN
Known title: DirectorCIK: 0001144511
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
Transaction History
| HCA | ▲ Buy | Grant | 509 | $0 | 4/28/2026 | View on chart |
| HCA | ▲ Buy | Grant | 645 | $0 | 4/29/2025 | View on chart |
| CVS | ▲ Buy | Grant | 2,331 | $133K | 11/21/2024 | View on chart |
| CVS | ▲ Buy | Grant | 2,314 | $133K | 5/16/2024 | View on chart |
| HCA | ▲ Buy | Grant | 610 | $0 | 4/29/2024 | View on chart |
| CVS | ▲ Buy | Grant | 1,925 | $133K | 11/15/2023 | View on chart |
| CVS | ▲ Buy | Grant | 1,437 | $100K | 5/18/2023 | View on chart |
| HCA | ▲ Buy | Grant | 663 | $0 | 4/24/2023 | View on chart |
| CVS | ▲ Buy | Grant | 1,402 | $133K | 11/17/2022 | View on chart |
| CVS | ▲ Buy | Grant | 1,358 | $133K | 5/11/2022 | View on chart |
| HCA | ▲ Buy | Grant | 902 | $0 | 4/25/2022 | View on chart |
| CVS | ▲ Buy | Grant | 1,334 | $124K | 11/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns
HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns. HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.